Crinetics Pharmaceuticals, Inc.
CRNX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $4 | $2 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $4 | $2 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -74.1% | -15.3% | 339.4% | – |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | -168% | 100% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -32,345.4% | -5,519.8% | -3,523.3% | -9,905.4% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -28,720.7% | -5,345.9% | -3,460.4% | -9,985.3% |
| EPS Diluted | -3.69 | -3.69 | -3.15 | -2.8 |
| % Growth | 0% | -17.1% | -12.5% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |